1
|
Hirota K, Yamashita A, Abe E, Yamaji T, Azushima K, Tanaka S, Taguchi S, Tsukamoto S, Wakui H, Tamura K. miR-125a-5p/miR-125b-5p contributes to pathological activation of angiotensin II-AT1R in mouse distal convoluted tubule cells by the suppression of Atrap. J Biol Chem 2023; 299:105478. [PMID: 37981211 PMCID: PMC10755798 DOI: 10.1016/j.jbc.2023.105478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Revised: 11/06/2023] [Accepted: 11/10/2023] [Indexed: 11/21/2023] Open
Abstract
The renin-angiotensin system plays a crucial role in the regulation of blood pressure. Activation of the angiotensin II (Ang II)-Ang II type 1 receptor (AT1R) signaling pathway contributes to the pathogenesis of hypertension and subsequent organ damage. AT1R-associated protein (ATRAP) has been identified as an endogenous inhibitory protein of the AT1R pathological activation. We have shown that mouse Atrap (Atrap) represses various Ang II-AT1R-mediated pathologies, including hypertension in mice. The expression of human ATRAP (ATRAP)/Atrap can be altered in various pathological states in humans and mice, such as Ang II stimulation and serum starvation. However, the regulatory mechanisms of ATRAP/Atrap are not yet fully elucidated. miRNAs are 21 to 23 nucleotides of small RNAs that post-transcriptionally repress gene expression. Single miRNA can act on hundreds of target mRNAs, and numerous miRNAs have been identified as the Ang II-AT1R signaling-associated disease phenotype modulator, but nothing is known about the regulation of ATRAP/Atrap. In the present study, we identified miR-125a-5p/miR-125b-5p as the evolutionarily conserved miRNAs that potentially act on ATRAP/Atrap mRNA. Further analysis revealed that miR-125a-5p/miR-125b-5p can directly repress both ATRAP and Atrap. In addition, the inhibition of miR-125a-5p/miR-125b-5p resulted in the suppression of the Ang II-AT1R signaling in mouse distal convoluted tubule cells. Taken together, miR-125a-5p/miR-125b-5p activates Ang II-AT1R signaling by the suppression of ATRAP/Atrap. Our results provide new insights into the potential approaches for achieving the organ-protective effects by the repression of the miR-125 family associated with the enhancement of ATRAP/Atrap expression.
Collapse
Affiliation(s)
- Keigo Hirota
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Akio Yamashita
- Department of Investigative Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
| | - Eriko Abe
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Takahiro Yamaji
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Kengo Azushima
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Shohei Tanaka
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Shinya Taguchi
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Shunichiro Tsukamoto
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Hiromichi Wakui
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Kouichi Tamura
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
| |
Collapse
|
2
|
Han X, Jiang S, Gu Y, Ding L, Zhao E, Cao D, Wang X, Wen Y, Pan Y, Yan X, Duan L, Sun M, Zhou T, Liu Y, Hu H, Ye Q, Gao S. HUNK inhibits epithelial-mesenchymal transition of CRC via direct phosphorylation of GEF-H1 and activating RhoA/LIMK-1/CFL-1. Cell Death Dis 2023; 14:327. [PMID: 37193711 DOI: 10.1038/s41419-023-05849-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2022] [Revised: 04/26/2023] [Accepted: 05/02/2023] [Indexed: 05/18/2023]
Abstract
Epithelial-mesenchymal transition (EMT) is associated with the invasive and metastatic phenotypes in colorectal cancer (CRC). However, the mechanisms underlying EMT in CRC are not completely understood. In this study, we find that HUNK inhibits EMT and metastasis of CRC cells via its substrate GEF-H1 in a kinase-dependent manner. Mechanistically, HUNK directly phosphorylates GEF-H1 at serine 645 (S645) site, which activates RhoA and consequently leads to a cascade of phosphorylation of LIMK-1/CFL-1, thereby stabilizing F-actin and inhibiting EMT. Clinically, the levels of both HUNK expression and phosphorylation S645 of GEH-H1 are not only downregulated in CRC tissues with metastasis compared with that without metastasis, but also positively correlated among these tissues. Our findings highlight the importance of HUNK kinase direct phosphorylation of GEF-H1 in regulation of EMT and metastasis of CRC.
Collapse
Affiliation(s)
- Xiaoqi Han
- Medical School of Guizhou University, Guiyang, 550025, China
- Shanxi Academy of Advanced Research and Innovation, Taiyuan, 030032, China
- Zhongda Hospital, School of Life Sciences and Technology, Advanced Institute for Life and Health, Southeast University, Nanjing, 210096, China
| | - Siyuan Jiang
- Zhongda Hospital, Medical School, Advanced Institute for Life and Health, Southeast University, Nanjing, 210096, China
| | - Yinmin Gu
- Zhongda Hospital, Medical School, Advanced Institute for Life and Health, Southeast University, Nanjing, 210096, China
| | - Lihua Ding
- Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Collaborative Innovation Center for Cancer Medicine, Beijing, 100850, China
| | - Enhao Zhao
- Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 201200, China
| | - Dongxing Cao
- Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 201200, China
| | - Xiaodong Wang
- Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, 215163, China
| | - Ya Wen
- Medical School of Guizhou University, Guiyang, 550025, China
- Shanxi Academy of Advanced Research and Innovation, Taiyuan, 030032, China
| | - Yongbo Pan
- Shanxi Academy of Advanced Research and Innovation, Taiyuan, 030032, China
| | - Xin Yan
- Shanxi Academy of Advanced Research and Innovation, Taiyuan, 030032, China
| | - Liqiang Duan
- Shanxi Academy of Advanced Research and Innovation, Taiyuan, 030032, China
| | - Minxuan Sun
- Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, 215163, China
| | - Tao Zhou
- Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, 215163, China
| | - Yajuan Liu
- Shanxi Academy of Advanced Research and Innovation, Taiyuan, 030032, China
| | - Hongbo Hu
- Center for Immunology and Hematology, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Sichuan, 610044, China.
| | - Qinong Ye
- Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Collaborative Innovation Center for Cancer Medicine, Beijing, 100850, China.
| | - Shan Gao
- Zhongda Hospital, School of Life Sciences and Technology, Advanced Institute for Life and Health, Southeast University, Nanjing, 210096, China.
| |
Collapse
|
3
|
Xu C, Chen Y, Wang F, Xie S, Yang T. Soluble (Pro)Renin Receptor as a Negative Regulator of NCC (Na +-Cl - Cotransporter) Activity. Hypertension 2021; 78:1027-1038. [PMID: 34495675 PMCID: PMC9212213 DOI: 10.1161/hypertensionaha.121.16981] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2021] [Accepted: 06/02/2021] [Indexed: 12/15/2022]
Abstract
[Figure: see text].
Collapse
Affiliation(s)
- Chuanming Xu
- Internal Medicine, University of Utah and Veterans Affairs Medical Center, Salt Lake City, Utah, the United States
- Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China
| | - Yanting Chen
- Internal Medicine, University of Utah and Veterans Affairs Medical Center, Salt Lake City, Utah, the United States
| | - Fei Wang
- Internal Medicine, University of Utah and Veterans Affairs Medical Center, Salt Lake City, Utah, the United States
| | - Shiying Xie
- Institute of Hypertension, Sun Yat-sen University School of Medicine, Guangzhou, China
| | - Tianxin Yang
- Internal Medicine, University of Utah and Veterans Affairs Medical Center, Salt Lake City, Utah, the United States
| |
Collapse
|
4
|
Zambrano JN, Neely BA, Yeh ES. Hormonally up-regulated neu-associated kinase: A novel target for breast cancer progression. Pharmacol Res 2017; 119:188-194. [PMID: 28189783 PMCID: PMC5392418 DOI: 10.1016/j.phrs.2017.02.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Revised: 02/06/2017] [Accepted: 02/07/2017] [Indexed: 12/26/2022]
Abstract
Hormonally up-regulated neu-associated Kinase (Hunk) is a protein kinase that was originally identified in the murine mammary gland and has been shown to be highly expressed in Human Epidermal Growth Factor Receptor 2 positive (HER2+/ErbB2+) breast cancer cell lines as well as MMTV-neu derived mammary tumor cell lines. However, the physiological role of Hunk has been largely elusive since its identification. Though Hunk is predicted to be a Serine/Threonine (Ser/Thr) protein kinase with homology to the SNF1/AMPK family of protein kinases, there are no known Hunk substrates that have been identified to date. Recent work demonstrates a role for Hunk in HER2+/ErbB2+ breast cancer progression, including drug resistance to HER2/ErbB2 inhibitors, with Hunk potentially acting downstream of HER2/ErbB2 and the PI3K/Akt pathway. These studies have collectively shown that Hunk plays a vital role in promoting mammary tumorigenesis, as Hunk knockdown via shRNA in xenograft tumor models or crossing MMTV-neu or Pten-deficient genetically engineered mouse models into a Hunk knockout (Hunk-/-) background impairs mammary tumor growth in vivo. Because the majority of HER2+/ErbB2+ breast cancer patients acquire drug resistance to HER2/ErbB2 inhibitors, the characterization of novel drug targets like Hunk that have the potential to simultaneously suppress tumorigenesis and potentially enhance efficacy of current therapeutics is an important facet of drug development. Therefore, work aimed at uncovering specific regulatory functions for Hunk that could contribute to this protein kinase's role in both tumorigenesis and drug resistance will be informative. This review focuses on what is currently known about this under-studied protein kinase, and how targeting Hunk may prove to be a potential therapeutic target for the treatment of breast cancer.
Collapse
Affiliation(s)
- Joelle N Zambrano
- Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina Charleston, SC, USA.
| | - Benjamin A Neely
- Marine Biochemical Sciences, National Institute of Standards and Technology, Charleston, SC, USA.
| | - Elizabeth S Yeh
- Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina Charleston, SC, USA.
| |
Collapse
|
5
|
Impaired nitric oxide production and increased blood pressure in systemic heterozygous ATP2B1 null mice. J Hypertens 2015; 32:1415-23; discussion 1423. [PMID: 24805951 DOI: 10.1097/hjh.0000000000000206] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
BACKGROUND In the 'Millennium Genome Project', we identified ATP2B1 as a gene responsible for hypertension through single-nucleotide polymorphism analysis. The ATP2B1 gene encodes the plasma membrane calcium ATPase isoform 1, which contributes to the maintenance of intracellular calcium homeostasis by removing calcium ions. METHOD Since ATP2B1 knockout mice are reported to be embryo-lethal, we generated systemic heterozygous ATP2B1 null (ATP2B1(+/-)) mice, and evaluated the implication of ATP2B1 in blood pressure. RESULTS ATP2B1(+/-) mice revealed significantly higher SBP as measured by a radiotelemetric method. Phenylephrine-induced vasoconstriction was significantly increased in vascular rings from ATP2B1(+/-) mice, and the difference in this contraction disappeared in the presence of a nitric oxide synthase (NOS) inhibitor. Vasorelaxation to acetylcholine was significantly attenuated in vascular rings from ATP2B1(+/-) mice. In addition, cultured endothelial cells of ATP2B1(+/-) mice showed that the phosphorylation (Ser-1177) level of endothelial NOS protein was significantly lower, and nitric oxide production in endothelial cells and aorta was lower compared with those in control mice. In contrast, neural NOS expression in vascular smooth muscle cells from ATP2B1(+/-) mice and control mice were not significantly different. CONCLUSION These results suggest that decreased ATP2B1 gene expression is associated with impaired endothelial NOS activity and nitric oxide production, and the ATP2B1 gene plays a crucial role in the regulation of blood pressure.
Collapse
|
6
|
Reed KR, Korobko IV, Ninkina N, Korobko EV, Hopkins BR, Platt JL, Buchman V, Clarke AR. Hunk/Mak-v is a negative regulator of intestinal cell proliferation. BMC Cancer 2015; 15:110. [PMID: 25881306 PMCID: PMC4367870 DOI: 10.1186/s12885-015-1087-2] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2014] [Accepted: 02/19/2015] [Indexed: 11/10/2022] Open
Abstract
Background Conditional deletion of the tumour suppressor gene Apc within the murine intestine results in acute Wnt signalling activation. The associated over-expression of a myriad of Wnt signalling target genes yields phenotypic alterations that encompass many of the hallmarks of neoplasia. Previous transcriptomic analysis aimed at identifying genes that potentially play an important role in this process, inferred the Hormonally upregulated Neu-associated kinase (HUNK/Mak-v/Bstk1) gene as a possible candidate. Hunk is a SNF1 (sucrose non fermenting 1)-related serine/threonine kinase with a proposed association with many different tumour types, including colorectal cancer. Methods Here we describe the generation of a novel Hunk kinase deficient mouse which has been used to investigate the involvement of Hunk-kinase activity in intestinal homeostasis and tumourigenesis. Results We show that in the morphologically normal intestine, Hunk-kinase negatively regulates epithelial cell proliferation. However, the increase in cell proliferation observed in the Hunk kinase deficient intestine is counteracted by increased cell migration, thereby maintaining intestinal homeostasis. Using qRT-PCR, we further demonstrate that Hunk is significantly over-expressed in Apc deficient / Wnt-signalling activated intestinal tissue. Using the classical intestinal tumourigenesis ApcMin mouse model we show that loss of Hunk-kinase activity significantly reduced tumour initiation rates in the small intestine. However, an accompanying increase in the size of the tumours counteracts the impact this has on overall tumour burden or subsequently survival. Conclusions In the intestinal setting we demonstrate that Hunk has a role in normal intestinal proliferation and homeostasis and, although it does not alter overall survival rates, activity of this kinase does impact on tumour initiation rates during the early stages in tumourigenesis in the small intestine. Electronic supplementary material The online version of this article (doi:10.1186/s12885-015-1087-2) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Karen R Reed
- University of Cardiff, European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff, CF10 3AX, UK.
| | - Igor V Korobko
- School of Biosciences, University of Cardiff, Cardiff, CF10 3AX, UK. .,Russian Academy of Sciences, Institute of Gene Biology, 34/5 Vavilov street, Moscow, 119334, Russia Federation.
| | - Natalia Ninkina
- School of Biosciences, University of Cardiff, Cardiff, CF10 3AX, UK. .,Institute of General Pathology and Pathophysiology of Russian Academy of Medical Science, 8 Baltijskaya str, Moscow, 125315, Russian Federation.
| | - Elena V Korobko
- Russian Academy of Sciences, Institute of Gene Biology, 34/5 Vavilov street, Moscow, 119334, Russia Federation.
| | - Ben R Hopkins
- School of Biosciences, University of Cardiff, Cardiff, CF10 3AX, UK.
| | - James L Platt
- School of Biosciences, University of Cardiff, Cardiff, CF10 3AX, UK.
| | - Vladimir Buchman
- School of Biosciences, University of Cardiff, Cardiff, CF10 3AX, UK.
| | - Alan R Clarke
- University of Cardiff, European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff, CF10 3AX, UK.
| |
Collapse
|
7
|
Ishigami T, Kino T, Chen L, Minegishi S, Araki N, Umemura M, Abe K, Sasaki R, Yamana H, Umemura S. Identification of bona fide alternative renin transcripts expressed along cortical tubules and potential roles in promoting insulin resistance in vivo without significant plasma renin activity elevation. Hypertension 2014; 64:125-33. [PMID: 24777979 DOI: 10.1161/hypertensionaha.114.03394] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Renin belongs to a family of aspartyl proteases and is the rate-limiting enzyme in the synthesis of the potent vasoactive peptide angiotensin II. Processing of renal renin has been extensively investigated in juxtaglomerular granular cells, in which prorenin and active renin are present in secretory condensed granules. Previous studies demonstrated alternative renin transcription in rat adrenal glands. Different studies reported novel intracellular forms of renin deduced from novel 5' variants derived from renin mRNA in both mice and humans. Comprehensive detailed studies in genetically engineered mice showed that both a secreted and an intracellular form of renin plays divergent mechanism regulating fluid intake and metabolism by the brain renin-angiotensin system; however, the presence, regulation, and functions of these renin isoforms in kidney and adrenal gland are not fully understood in mice. To investigate the characteristics of renin isoforms in mice, we performed a systematic inventory of renin transcripts of mice with and without a duplication of the renin gene alternatively from previous studies. We discovered a novel isoform of renin of the Ren2 gene, which conserved functionally important residues of the prosegment and incomplete isoforms of the Ren1C/D gene lacking a pre-pro segment. In situ hybridization assays revealed alternative renin isoforms expressed along cortical tubules. Newly generated transgenic mice with systemic overexpression of alternative renin transcript showed enhanced local angiotensin II generation without elevation of plasma renin activity and systemic insulin resistance in vivo, providing new pathophysiological insights into insulin resistance exaggerated by bona fide renin isoform.
Collapse
Affiliation(s)
- Tomoaki Ishigami
- From the Department of Medical Science and Cardio-Renal Medicine, Yokohama City University, Graduate School of Medicine, Yokohama, Japan.
| | - Tabito Kino
- From the Department of Medical Science and Cardio-Renal Medicine, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
| | - Lin Chen
- From the Department of Medical Science and Cardio-Renal Medicine, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
| | - Shintaro Minegishi
- From the Department of Medical Science and Cardio-Renal Medicine, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
| | - Naomi Araki
- From the Department of Medical Science and Cardio-Renal Medicine, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
| | - Masanari Umemura
- From the Department of Medical Science and Cardio-Renal Medicine, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
| | - Kaito Abe
- From the Department of Medical Science and Cardio-Renal Medicine, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
| | - Rie Sasaki
- From the Department of Medical Science and Cardio-Renal Medicine, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
| | - Hisako Yamana
- From the Department of Medical Science and Cardio-Renal Medicine, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
| | - Satoshi Umemura
- From the Department of Medical Science and Cardio-Renal Medicine, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
| |
Collapse
|
8
|
Ohsawa M, Tamura K, Wakui H, Maeda A, Dejima T, Kanaoka T, Azushima K, Uneda K, Tsurumi-Ikeya Y, Kobayashi R, Matsuda M, Uchida S, Toya Y, Kobori H, Nishiyama A, Yamashita A, Ishikawa Y, Umemura S. Deletion of the angiotensin II type 1 receptor-associated protein enhances renal sodium reabsorption and exacerbates angiotensin II-mediated hypertension. Kidney Int 2014; 86:570-81. [PMID: 24694992 PMCID: PMC4149871 DOI: 10.1038/ki.2014.95] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2013] [Revised: 02/07/2014] [Accepted: 02/13/2014] [Indexed: 12/13/2022]
Abstract
Angiotensin II type 1 receptor (AT1R)–associated protein (ATRAP) promotes AT1R internalization along with suppression of pathological activation of tissue AT1R signaling. However, the functional significance of ATRAP in renal sodium handling and blood pressure regulation under pathological stimuli is not fully resolved. Here we show the blood pressure of mice with a gene-targeted disruption of ATRAP was comparable to that of wild-type mice at baseline. However, in ATRAP-knockout mice, angiotensin II–induced hypertension was exacerbated and the extent of positive sodium balance was increased by angiotensin II. Renal expression of the sodium-proton antiporter 3, a major sodium transporter in the proximal tubules, urinary pH, renal angiotensinogen production, and angiotensin II content was unaffected. Stimulation of the renal expression and activity of the epithelial sodium channel (ENaC), a major sodium transporter in the distal tubules, was significantly enhanced by chronic angiotensin II infusion. The circulating and urinary aldosterone levels were comparable. The blood pressure response and renal ENaC expression by aldosterone were not affected. Thus, ATRAP deficiency exacerbated angiotensin II–mediated hypertension by pathological activation of renal tubular AT1R by angiotensin II. This directly stimulates ENaC in the distal tubules and enhances sodium retention in an aldosterone-independent manner.
Collapse
Affiliation(s)
- Masato Ohsawa
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Kouichi Tamura
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Hiromichi Wakui
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Akinobu Maeda
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Toru Dejima
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Tomohiko Kanaoka
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Kengo Azushima
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Kazushi Uneda
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Yuko Tsurumi-Ikeya
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Ryu Kobayashi
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Miyuki Matsuda
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Shinichi Uchida
- Department of Nephrology, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan
| | - Yoshiyuki Toya
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Hiroyuki Kobori
- Department of Pharmacology, Kagawa University School of Medicine, Kagawa, Japan
| | - Akira Nishiyama
- Department of Pharmacology, Kagawa University School of Medicine, Kagawa, Japan
| | - Akio Yamashita
- Department of Molecular Biology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Yoshihiro Ishikawa
- Cardiovascular Research Institute, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Satoshi Umemura
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| |
Collapse
|
9
|
Wakui H, Dejima T, Tamura K, Uneda K, Azuma K, Maeda A, Ohsawa M, Kanaoka T, Azushima K, Kobayashi R, Matsuda M, Yamashita A, Umemura S. Activation of angiotensin II type 1 receptor-associated protein exerts an inhibitory effect on vascular hypertrophy and oxidative stress in angiotensin II-mediated hypertension. Cardiovasc Res 2013; 100:511-9. [PMID: 24189624 DOI: 10.1093/cvr/cvt225] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
AIMS Activation of tissue angiotensin II (Ang II) type 1 receptor (AT1R) plays an important role in the development of vascular remodelling. We have shown that the AT1R-associated protein (ATRAP/Agtrap), a specific binding protein of AT1R, functions as an endogenous inhibitor to prevent pathological activation of the tissue renin-angiotensin system. In this study, we investigated the effects of ATRAP on Ang II-induced vascular remodelling. METHODS AND RESULTS Transgenic (Tg) mice with a pattern of aortic vascular-dominant overexpression of ATRAP were obtained, and Ang II or vehicle was continuously infused into Tg and wild-type (Wt) mice via an osmotic minipump for 14 days. Although blood pressure of Ang II-infused Tg mice was comparable with that of Ang II-infused Wt mice, the Ang II-mediated development of aortic vascular hypertrophy was partially inhibited in Tg mice compared with Wt mice. In addition, Ang II-mediated up-regulation of vascular Nox4 and p22(phox), NADPH oxidase components, and 4-HNE, a marker of reactive oxygen species (ROS) generation, was significantly suppressed in Tg mice, with a concomitant inhibition of activation of aortic vascular p38MAPK and JNK by Ang II. This protection afforded by vascular ATRAP against Ang II-induced activation of NADPH oxidase is supported by in vitro experimental data using adenoviral transfer of recombinant ATRAP. CONCLUSION These results indicate that activation of aortic vascular ATRAP partially inhibits the Nox4/p22(phox)-ROS-p38MAPK/JNK pathway and pathological aortic hypertrophy provoked by Ang II-mediated hypertension, thereby suggesting ATRAP as a novel receptor-binding modulator of vascular pathophysiology.
Collapse
Affiliation(s)
- Hiromichi Wakui
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Matsuda M, Tamura K, Wakui H, Maeda A, Ohsawa M, Kanaoka T, Azushima K, Uneda K, Haku S, Tsurumi-Ikeya Y, Toya Y, Maeshima Y, Yamashita A, Umemura S. Upstream stimulatory factors 1 and 2 mediate the transcription of angiotensin II binding and inhibitory protein. J Biol Chem 2013; 288:19238-49. [PMID: 23653383 PMCID: PMC3696694 DOI: 10.1074/jbc.m113.451054] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
The angiotensin II type 1 receptor (AT1R)-associated protein (ATRAP/Agtrap) promotes constitutive internalization of the AT1R so as to specifically inhibit the pathological activation of its downstream signaling yet preserve the base-line physiological signaling activity of the AT1R. Thus, tissue-specific regulation of Agtrap expression is relevant to the pathophysiology of cardiovascular and renal disease. However, the regulatory mechanism of Agtrap gene expression has not yet been fully elucidated. In this study, we show that the proximal promoter region from −150 to +72 of the mouse Agtrap promoter, which contains the X-box, E-box, and GC-box consensus motifs, is able to elicit substantial transcription of the Agtrap gene. Among these binding motifs, we showed that the E-box specifically binds upstream stimulatory factor (Usf) 1 and Usf2, which are known E-box-binding transcription factors. It is indicated that the E-box-Usf1/Usf2 binding regulates Agtrap expression because of the following: 1) mutation of the E-box to prevent Usf1/Usf2 binding reduces Agtrap promoter activity; 2) knockdown of Usf1 or Usf2 affects both endogenous Agtrap mRNA and Agtrap protein expression, and 3) the decrease in Agtrap mRNA expression in the afflicted kidney by unilateral ureteral obstruction is accompanied by changes in Usf1 and Usf2 mRNA. Furthermore, the results of siRNA transfection in mouse distal convoluted tubule cells and those of unilateral ureteral obstruction in the afflicted mouse kidney suggest that Usf1 decreases but Usf2 increases the Agtrap gene expression by binding to the E-box. The results also demonstrate a functional E-box-USF1/USF2 interaction in the human AGTRAP promoter, thereby suggesting that a strategy of modulating the E-box-USF1/USF2 binding has novel therapeutic potential.
Collapse
Affiliation(s)
- Miyuki Matsuda
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Ushio-Yamana H, Minegishi S, Ishigami T, Araki N, Umemura M, Tamura K, Maeda E, Kakizoe Y, Kitamura K, Umemura S. Renin angiotensin antagonists normalize aberrant activation of epithelial sodium channels in sodium-sensitive hypertension. Nephron Clin Pract 2013; 122:95-102. [PMID: 23594971 DOI: 10.1159/000348660] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2012] [Accepted: 02/02/2013] [Indexed: 11/19/2022] Open
Abstract
Epithelial sodium channels (ENaC) are ion transporters in the aldosterone-sensitive distal nephron that play an important role in sodium reabsorption in the terminal nephron. Our study of inbred C57Bl6/J mice given a high-sodium diet showed increased ENaC expression accompanied by tubular renin activation on qRT-PCR of laser-captured tubule specimens and Western blotting of membrane proteins, despite inhibition of aldosterone. Treatment with an angiotensin-converting-enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB) effectively lowered blood pressure. In addition to lowering blood pressure, ACEI and ARB inhibition downregulated ENaC and renin expression in renal tubules. These effects would act to suppress sodium reabsorption via ENaC and normalize molecular mechanisms that elevate blood pressure in response to increased salt intake.
Collapse
Affiliation(s)
- Hisako Ushio-Yamana
- Department of Medical Science and Cardio-Renal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Kobayashi Y, Hirawa N, Tabara Y, Muraoka H, Fujita M, Miyazaki N, Fujiwara A, Ichikawa Y, Yamamoto Y, Ichihara N, Saka S, Wakui H, Yoshida SI, Yatsu K, Toya Y, Yasuda G, Kohara K, Kita Y, Takei K, Goshima Y, Ishikawa Y, Ueshima H, Miki T, Umemura S. Mice Lacking Hypertension Candidate Gene ATP2B1 in Vascular Smooth Muscle Cells Show Significant Blood Pressure Elevation. Hypertension 2012; 59:854-60. [DOI: 10.1161/hypertensionaha.110.165068] [Citation(s) in RCA: 67] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Affiliation(s)
- Yusuke Kobayashi
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Nobuhito Hirawa
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Yasuharu Tabara
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Hidenori Muraoka
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Megumi Fujita
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Nobuko Miyazaki
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Akira Fujiwara
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Yasuhiro Ichikawa
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Yuichiro Yamamoto
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Naoaki Ichihara
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Sanae Saka
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Hiromichi Wakui
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Shin-ichiro Yoshida
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Keisuke Yatsu
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Yoshiyuki Toya
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Gen Yasuda
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Katsuhiko Kohara
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Yoshikuni Kita
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Kohtaro Takei
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Yoshio Goshima
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Yoshihiro Ishikawa
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Hirotsugu Ueshima
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Tetsuro Miki
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| | - Satoshi Umemura
- From the Departments of Medical Science and Cardiorenal Medicine (Y.K., M.F., N.M., A.F., N.I., S.S., H.W., S.Y., Y.T., S.U.) and Molecular Pharmacology and Neurobiology (H.M., K.T., Y.G.) and Cardiovascular Research Institute (Y.Ic., Y.Is.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Division of Nephrology and Hypertension (N.H., Y.Y., K.Y., G.Y.), Yokohama City University Medical Center, Yokohama, Japan; Department of Geriatric Medicine (Y.T., K.K., T.M.), Ehime
| |
Collapse
|
13
|
Prepubertal angiotensin blockade exerts long-term therapeutic effect through sustained ATRAP activation in salt-sensitive hypertensive rats. J Hypertens 2012; 29:1919-29. [PMID: 21844822 DOI: 10.1097/hjh.0b013e32834a5a46] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
OBJECTIVE We previously showed that the molecule interacting with Ang II type 1 receptor (AT1R), ATRAP, promotes AT1R internalization and attenuates AT1R-mediated pathological responses. In this study we examined whether the regulation of renal ATRAP expression is related to the development of salt-induced hypertension and renal injury as well as to the beneficial effects of AT1R blockade. METHODS AND RESULTS Dahl Iwai salt-sensitive hypertensive and Dahl Iwai salt-resistant rats were divided into six groups for the administration of vehicle or olmesartan either continuously from 3 to 16 weeks, or transiently from weaning to puberty (3-10 weeks), and fed high salt diet from 6 to 16 weeks. In Dahl Iwai salt-sensitive rats, not only continuous, but also prepubertal olmesartan treatment improved hypertension at 15 weeks. Renal ATRAP expression was suppressed in vehicle-treated Dahl Iwai salt-sensitive rats, concomitant with up-regulation of renal oxidative stress, inflammation and fibrosis-related markers such as p22phox, TGF-β, fibronectin, monocyte chemotactic protein-1 and type 1 collagen. However, prepubertal as well as continuous olmesartan treatment recovered the suppressed renal ATRAP expression and inhibited the renal activation of p22phox, TGF-β, fibronectin, MCP-1 and type 1 collagen. In Dahl Iwai salt-resistant rats, such suppression of renal ATRAP expression or induction of renal pathological responses by salt loading was not observed. CONCLUSIONS These results indicate that prepubertal transient blockade of AT1R signaling exerts a long-term therapeutic effect on salt-induced hypertension and renal injury in Dahl Iwai salt-sensitive rats, partly through a sustained enhancement of renal ATRAP expression, thereby suggesting ATRAP a novel molecular target in salt-induced hypertension and renal injury.
Collapse
|
14
|
Kalinichenko SV, Vikhreva PN, Korobko IV. Interaction between MAK-V protein kinase and synaptopodin. BIOCHEMISTRY (MOSCOW) 2011; 76:196-201. [PMID: 21568852 DOI: 10.1134/s0006297911020052] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
MAK-V protein kinase (also known as HUNK) was discovered more than decade ago but its functions and molecular mechanisms of action still remain mostly unknown. In an attempt to associate MAK-V with particular chains of molecular events, we searched for proteins interacting with the C-terminal domain of MAK-V protein kinase. We identified synaptopodin as a protein interaction partner for MAK-V and confirmed this interaction in various ways. Because synaptopodin is important for dendritic spine formation and plays a role in synaptic plasticity, our results might have significant impact on future studies for understanding the role of MAK-V in cells of the nervous system.
Collapse
Affiliation(s)
- S V Kalinichenko
- Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia.
| | | | | |
Collapse
|
15
|
Matsuda M, Tamura K, Wakui H, Dejima T, Maeda A, Ohsawa M, Kanaoka T, Haku S, Azushima K, Yamasaki H, Saito D, Hirose T, Maeshima Y, Nagashima Y, Umemura S. Involvement of Runx3 in the basal transcriptional activation of the mouse angiotensin II type 1 receptor-associated protein gene. Physiol Genomics 2011; 43:884-94. [PMID: 21586669 DOI: 10.1152/physiolgenomics.00005.2011] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
We previously cloned a molecule that interacts with angiotensin II type 1 (AT1) receptor to exert an inhibitory function on AT1 receptor signaling that we named ATRAP/Agtrap (for AT1 receptor-associated protein). In the present study we examined the regulation of basal ATRAP gene expression using renal distal convoluted tubule cells. We found that serum starvation upregulated basal expression of ATRAP gene, a response that required de novo mRNA and protein synthesis. Luciferase assay revealed that the proximal promoter region directs transcription and that a putative binding site of runt-related transcription factors (RBE) is important for transcriptional activation. The results of RBE-decoy transfection and endogenous knockdown by small interference RNA showed that the runt-related transcription factor Runx3 is involved in ATRAP gene expression. Chromatin immunoprecipitation assay also supported the binding of Runx3 to the ATRAP promoter in renal distal convoluted tubule cells. Immunohistochemistry demonstrated the expression of Runx3 and ATRAP proteins in the distal convoluted and connecting tubules of the kidney in consecutive sections. Furthermore, the Runx3 immunostaining was decreased together with a concomitant suppression of ATRAP expression in the affected kidney after 7 days of unilateral ureteral obstruction. These findings indicate that Runx3 plays a role in ATRAP gene expression in renal distal tubular cells both in vitro and in vivo.
Collapse
Affiliation(s)
- Miyuki Matsuda
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Korobko IV, Kalinichenko SV, Korobko EV, Ninkina NN, Kiselev SL, Buchman VL. Pro-survival activity of the MAK-V protein kinase in PC12 cells. Cell Cycle 2010; 9:4248-9. [PMID: 20978373 PMCID: PMC3055208 DOI: 10.4161/cc.9.20.13592] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2010] [Accepted: 09/11/2010] [Indexed: 02/07/2023] Open
Affiliation(s)
- Igor V Korobko
- Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia.
| | | | | | | | | | | |
Collapse
|
17
|
Wakui H, Tamura K, Matsuda M, Bai Y, Dejima T, Shigenaga AI, Masuda SI, Azuma K, Maeda A, Hirose T, Ishigami T, Toya Y, Yabana M, Minamisawa S, Umemura S. Intrarenal suppression of angiotensin II type 1 receptor binding molecule in angiotensin II-infused mice. Am J Physiol Renal Physiol 2010; 299:F991-F1003. [PMID: 20739392 DOI: 10.1152/ajprenal.00738.2009] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
ATRAP [ANG II type 1 receptor (AT1R)-associated protein] is a molecule which directly interacts with AT1R and inhibits AT1R signaling. The aim of this study was to examine the effects of continuous ANG II infusion on the intrarenal expression and distribution of ATRAP and to determine the role of AT1R signaling in mediating these effects. C57BL/6 male mice were subjected to vehicle or ANG II infusions at doses of 200, 1,000, or 2,500 ng·kg(-1)·min(-1) for 14 days. ANG II infusion caused significant suppression of ATRAP expression in the kidney but did not affect ATRAP expression in the testis or liver. Although only the highest ANG II dose (2,500 ng·kg(-1)·min(-1)) provoked renal pathological responses, such as an increase in the mRNA expression of angiotensinogen and the α-subunit of the epithelial sodium channel, ANG II-induced decreases in ATRAP were observed even at the lowest dose (200 ng·kg(-1)·min(-1)), particularly in the outer medulla of the kidney, based on immunohistochemical staining and Western blot analysis. The decrease in renal ATRAP expression by ANG II infusion was prevented by treatment with the AT1R-specific blocker olmesartan. In addition, the ANG II-mediated decrease in renal ATRAP expression through AT1R signaling occurred without an ANG II-induced decrease in plasma membrane AT1R expression in the kidney. On the other hand, a transgenic model increase in renal ATRAP expression beyond baseline was accompanied by a constitutive reduction of renal plasma membrane AT1R expression and by the promotion of renal AT1R internalization as well as the decreased induction of angiotensinogen gene expression in response to ANG II. These results suggest that the plasma membrane AT1R level in the kidney is modulated by intrarenal ATRAP expression under physiological and pathophysiological conditions in vivo.
Collapse
Affiliation(s)
- Hiromichi Wakui
- Dept. of Medical Science and Cardiorenal Medicine, Yokohama City Univ. Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Masuda SI, Tamura K, Wakui H, Maeda A, Dejima T, Hirose T, Toyoda M, Azuma K, Ohsawa M, Kanaoka T, Yanagi M, Yoshida SI, Mitsuhashi H, Matsuda M, Ishigami T, Toya Y, Suzuki D, Nagashima Y, Umemura S. Expression of angiotensin II type 1 receptor-interacting molecule in normal human kidney and IgA nephropathy. Am J Physiol Renal Physiol 2010; 299:F720-31. [PMID: 20685825 DOI: 10.1152/ajprenal.00667.2009] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
The intrarenal renin-angiotensin system plays a crucial role in the regulation of renal circulation and sodium reabsorption through the activation of vascular, glomerular, and tubular angiotensin II type 1 (AT(1)) receptor signaling. We previously cloned a molecule that specifically interacted with the murine AT(1) receptor to inhibit AT(1) receptor signaling, which we named ATRAP (for AT(1) receptor-associated protein). Since murine ATRAP was shown to be highly expressed in the kidney, in the present study we investigated expression and distribution of human ATRAP in normal kidney and renal biopsy specimens from patients with IgA nephropathy. In the normal human kidney, both ATRAP mRNA and protein were widely and abundantly distributed along the renal tubules from Bowman's capsule to the medullary collecting ducts. In all renal tubular epithelial cells, the ATRAP protein colocalized with the AT(1) receptor. In renal biopsy specimens with IgA nephropathy, a significant positive correlation between ATRAP and AT(1) receptor gene expression was observed. There was also a positive relationship between tubulointerstitial ATRAP expression and the estimated glomerular filtration rate in patients with IgA nephropathy. Furthermore, we examined the function of the tubular AT(1) receptor using an immortalized cell line of mouse distal convoluted tubule cells (mDCT) and found that overexpression of ATRAP by adenoviral gene transfer suppressed the angiotensin II-mediated increases in transforming growth factor-β production in mDCT cells. These findings suggest that ATRAP might play a role in balancing the renal renin-angiotensin system synergistically with the AT(1) receptor by counterregulatory effects in IgA nephropathy and propose an antagonistic effect of tubular ATRAP on AT(1) receptor signaling.
Collapse
Affiliation(s)
- Shin-ichiro Masuda
- Dept. of Medical Science and Cardiorenal Medicine, Yokohama City Univ. Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Wakui H, Tamura K, Tanaka Y, Matsuda M, Bai Y, Dejima T, Masuda SI, Shigenaga AI, Maeda A, Mogi M, Ichihara N, Kobayashi Y, Hirawa N, Ishigami T, Toya Y, Yabana M, Horiuchi M, Minamisawa S, Umemura S. Cardiac-Specific Activation of Angiotensin II Type 1 Receptor–Associated Protein Completely Suppresses Cardiac Hypertrophy in Chronic Angiotensin II–Infused Mice. Hypertension 2010; 55:1157-64. [DOI: 10.1161/hypertensionaha.109.147207] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
We cloned a novel molecule interacting with angiotensin II type 1 receptor, which we named ATRAP (for angiotensin II type 1 receptor–associated protein). Previous in vitro studies showed that ATRAP significantly promotes constitutive internalization of the angiotensin II type 1 receptor and further attenuates angiotensin II–mediated hypertrophic responses in cardiomyocytes. The present study was designed to investigate the putative functional role of ATRAP in cardiac hypertrophy by angiotensin II infusion in vivo. We first examined the effect of angiotensin II infusion on endogenous ATRAP expression in the heart of C57BL/6J wild-type mice. The angiotensin II treatment promoted cardiac hypertrophy, concomitant with a significant decrease in cardiac ATRAP expression, but without significant change in cardiac angiotensin II type 1 receptor expression. We hypothesized that a downregulation of the cardiac ATRAP to angiotensin II type 1 receptor ratio is involved in the pathogenesis of cardiac hypertrophy. To examine this hypothesis, we next generated transgenic mice expressing ATRAP specifically in cardiomyocytes under control of the α-myosin heavy chain promoter. In cardiac-specific ATRAP transgenic mice, the development of cardiac hypertrophy, activation of p38 mitogen-activated protein kinase, and expression of hypertrophy-related genes in the context of angiotensin II treatment were completely suppressed, in spite of there being no significant difference in blood pressure on radiotelemetry between the transgenic mice and littermate control mice. These results demonstrate that cardiomyocyte-specific overexpression of ATRAP in vivo abolishes the cardiac hypertrophy provoked by chronic angiotensin II infusion, thereby suggesting ATRAP to be a novel therapeutic target in cardiac hypertrophy.
Collapse
Affiliation(s)
- Hiromichi Wakui
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Kouichi Tamura
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Yutaka Tanaka
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Miyuki Matsuda
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Yunzhe Bai
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Toru Dejima
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Shin-ichiro Masuda
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Atsu-ichiro Shigenaga
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Akinobu Maeda
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Masaki Mogi
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Naoaki Ichihara
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Yusuke Kobayashi
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Nobuhito Hirawa
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Tomoaki Ishigami
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Yoshiyuki Toya
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Machiko Yabana
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Masatsugu Horiuchi
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Susumu Minamisawa
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| | - Satoshi Umemura
- From the Department of Medical Science and Cardiorenal Medicine (H.W., K.T., M.M., Y.B., T.D., S.M., A.S., A.M., N.I., Y.K., N.H., T.I., Y.T., M.Y., S.U.), Yokohama City University Graduate School of Medicine, Yokohama, Japan; Department of Molecular Cardiovascular Biology and Pharmacology (M.M., M.H.), Ehime University, Graduate School of Medicine, Ehime, Japan; Department of Life Science and Medical Bio-science (S.M.), Waseda University, Tokyo, Japan
| |
Collapse
|
20
|
Kalinichenko SV, Korobko EV, Korobko IV. Membrane localization of the MAK-V protein kinase. BIOCHEMISTRY (MOSCOW) 2008; 73:278-82. [PMID: 18393762 DOI: 10.1134/s0006297908030061] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Activities of many proteins including protein kinases are often regulated by their dynamic association with specific intracellular compartments. MAK-V is an AMPK-like protein kinase with poorly characterized functions and mechanisms of action. Similarly to many other protein kinases, association of MAK-V with specific intracellular compartments could be essential for its proper functions. In this work, we studied subcellular distribution of exogenously produced and endogenous MAK-V proteins in mammalian cells using biochemical cell fractioning aiming to supplement data on MAK-V intracellular localization studied by immunocytochemical methods. We found that a significant portion of MAK-V protein in mammalian cells is associated with membranes. Moreover, MAK-V expressed in yeast was also targeted to membrane, thus suggesting an evolutionarily conservative mechanism of MAK-V membrane association. Based on the ability of various MAK-V deletion mutants to localize to membrane and comparison of MAK-V amino acid sequences from different species, we suggest a possible mechanism governing MAK-V association with intracellular membranes.
Collapse
Affiliation(s)
- S V Kalinichenko
- Institute of Gene Biology, Russian Academy of Sciences, ul. Vavilova 34/5, Moscow, Russia
| | | | | |
Collapse
|